Biotechnology News

Lift Therapeutics today announced the appointment of Eva Ehrnrooth as Executive Head of Clinical Development and Chau Khuong to its Board of Directors.

COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...

KØBENHAVN, Danmark, 28. september 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 1. september 2026, hvorunder selskabet vil...

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

11,1 millions d’euros de trésorerie au 30 juin 2026 ; horizon de financement confirmé jusqu’à fin décembre 2026La Société poursuit activement ses interactions avec les investisseurs institutionnels...

Positive interim data from Phase Ib proof-of-concept trial will be presented at the IPPF Scientific Symposium on Pemphigus and Pemphigoid and at EADV Congress 2026Data positions nebaprubart as a...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the...

Ad hoc announcement pursuant to Art. 53 LR U.S. clinical hold remains in place; study continues in all other countries Company initiates expansion of clinical sites and enrollment in Europe, Asia...